Speakers: Dr. Richard Evans, SSR Co-Founder, Portfolio Advisor | Rob Moffat, Portfolio Manager, Middlefield
Moderator: Dean Orrico, President & CEO, Middlefield
This session dove into the transformative potential of key innovations in healthcare, including the growth of the weight-loss drug market. Rob Moffat and Dr. Richard Evans discussed the immense financial potential of drugs like Ozempic, which, in aggregate, could reach $130 billion in revenue by 2030. The conversation also covered the role of artificial intelligence in reshaping drug discovery and patient care, with AI applications expected to revolutionize diagnostics and clinical outcomes. These advancements make healthcare an exciting, high-growth sector to watch in the coming years.
Key takeaway: The intersection of AI and healthcare, coupled with breakthrough weight-loss drugs, is driving a new wave of innovation that could reshape the entire healthcare sector.
Disclaimer
This material has been prepared for informational purposes only without regard to any particular user’s investment objectives or financial situation. This communication constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described herein is suitable or appropriate for you. Investment decisions should be made with guidance from a qualified professional. The opinions contained in this report are solely those of Middlefield Limited (“ML”) and are subject to change without notice. ML makes every effort to ensure that the information has been derived from sources believed to reliable, but we cannot represent that they are complete or accurate. However, ML assumes no responsibility for any losses or damages, whether direct or indirect which arise from the use of this information. ML is under no obligation to update the information contained herein. This document is not to be construed as a solicitation, recommendation or offer to buy or sell any security, financial product or instrument.
This video was filmed on September 10, 2024.
Forward-Looking Information
Certain statements in this press release may be viewed as forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, intentions, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “is expected”, “anticipates”, “plans”, “estimates” or “intends” (or negative or grammatical variations thereof), or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements including as a result of changes in the general economic and political environment, changes in applicable legislation, and the performance of each fund. There are no assurances the funds can fulfill such forward-looking statements and the funds do not undertake any obligation to update such statements. Such forward-looking statements are only predictions; actual events or results may differ materially as a result of risks facing one or more of the funds, many of which are beyond the control of the funds.
